UA97233C2 - Процес виробництва вакцин - Google Patents
Процес виробництва вакцин Download PDFInfo
- Publication number
- UA97233C2 UA97233C2 UAA200714085A UAA200714085A UA97233C2 UA 97233 C2 UA97233 C2 UA 97233C2 UA A200714085 A UAA200714085 A UA A200714085A UA A200714085 A UAA200714085 A UA A200714085A UA 97233 C2 UA97233 C2 UA 97233C2
- Authority
- UA
- Ukraine
- Prior art keywords
- solution
- saccharide
- conjugate
- minutes
- added
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 54
- 230000008569 process Effects 0.000 title abstract description 15
- 229960005486 vaccine Drugs 0.000 title description 28
- 238000004519 manufacturing process Methods 0.000 title description 3
- 150000001720 carbohydrates Chemical class 0.000 abstract description 77
- 239000000203 mixture Substances 0.000 abstract description 27
- 150000001718 carbodiimides Chemical class 0.000 abstract description 26
- 238000006243 chemical reaction Methods 0.000 abstract description 26
- 102000004169 proteins and genes Human genes 0.000 abstract description 22
- 108090000623 proteins and genes Proteins 0.000 abstract description 22
- 230000002163 immunogen Effects 0.000 abstract description 18
- 230000021615 conjugation Effects 0.000 abstract description 15
- 238000009833 condensation Methods 0.000 abstract description 7
- 230000005494 condensation Effects 0.000 abstract description 7
- 239000011541 reaction mixture Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 116
- 229960000814 tetanus toxoid Drugs 0.000 description 63
- 150000004676 glycans Chemical class 0.000 description 54
- 229920001282 polysaccharide Polymers 0.000 description 54
- 239000005017 polysaccharide Substances 0.000 description 54
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 29
- 230000004048 modification Effects 0.000 description 24
- 238000012986 modification Methods 0.000 description 24
- 210000004379 membrane Anatomy 0.000 description 21
- 239000012528 membrane Substances 0.000 description 21
- 239000011148 porous material Substances 0.000 description 20
- 238000011026 diafiltration Methods 0.000 description 19
- 238000005194 fractionation Methods 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 15
- 108010078791 Carrier Proteins Proteins 0.000 description 13
- 102000014914 Carrier Proteins Human genes 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 125000006850 spacer group Chemical group 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 241001643597 Evas Species 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 7
- 238000010979 pH adjustment Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006640 acetylation reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000012506 Sephacryl® Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000004445 quantitative analysis Methods 0.000 description 5
- 239000000344 soap Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 201000005702 Pertussis Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 108010077805 Bacterial Proteins Proteins 0.000 description 3
- 201000005505 Measles Diseases 0.000 description 3
- 208000005647 Mumps Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000010805 mumps infectious disease Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 229960005367 tetanus antitoxin Drugs 0.000 description 3
- -1 1-cyano-4-dimethylamino-pyridine tetrafluoroborate Chemical compound 0.000 description 2
- ALEBYBVYXQTORU-UHFFFAOYSA-N 6-hydrazinyl-6-oxohexanoic acid Chemical compound NNC(=O)CCCCC(O)=O ALEBYBVYXQTORU-UHFFFAOYSA-N 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229960003983 diphtheria toxoid Drugs 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- YIJFIIXHVSHQEN-UHFFFAOYSA-N 3-Aminocaproic acid Chemical compound CCCC(N)CC(O)=O YIJFIIXHVSHQEN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 101710183389 Pneumolysin Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101100208039 Rattus norvegicus Trpv5 gene Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229920006170 Therban® Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102100029513 Ubiquinol-cytochrome-c reductase complex assembly factor 2 Human genes 0.000 description 1
- KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229940025656 proin Drugs 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 208000027301 sporadic infantile bilateral striatal necrosis Diseases 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0513069.5A GB0513069D0 (en) | 2005-06-27 | 2005-06-27 | Immunogenic composition |
| PCT/EP2006/006270 WO2007000343A2 (en) | 2005-06-27 | 2006-06-23 | Process for manufacturing vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA97233C2 true UA97233C2 (uk) | 2012-01-25 |
Family
ID=34856207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200714085A UA97233C2 (uk) | 2005-06-27 | 2006-06-23 | Процес виробництва вакцин |
Country Status (7)
| Country | Link |
|---|---|
| CN (4) | CN101247827B (zh) |
| ES (1) | ES2367918T5 (zh) |
| FR (1) | FR12C0060I2 (zh) |
| GB (1) | GB0513069D0 (zh) |
| NO (1) | NO2021022I1 (zh) |
| UA (1) | UA97233C2 (zh) |
| ZA (3) | ZA200710853B (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201404447WA (en) * | 2012-01-30 | 2014-08-28 | Serum Inst India Ltd | Immunogenic composition |
| MX363511B (es) * | 2012-08-16 | 2019-03-26 | Pfizer | Proceso de glucoconjugación y composiciones. |
| SI3544637T1 (sl) * | 2016-11-25 | 2021-02-26 | Glaxosmithkline Biologicals S.A. | Nativni OMV-antigen konjugati in njihova uporaba |
| CN109879967A (zh) * | 2017-12-15 | 2019-06-14 | 苏州和锐生物科技有限公司 | 一种乙酰氨基葡萄糖偶联物的制备方法及应用 |
| CN110251667A (zh) * | 2018-05-11 | 2019-09-20 | 武汉博沃生物科技有限公司 | 一种免疫组合制剂及其制备方法和应用 |
| CN115819616A (zh) * | 2021-07-28 | 2023-03-21 | 江苏瑞科生物技术股份有限公司 | 一种基因重组vzv融合蛋白及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5180815A (en) * | 1988-04-13 | 1993-01-19 | Fuji Photo Film Co., Ltd. | Modified protein for carrying hapten |
| ATE534402T1 (de) * | 2000-06-29 | 2011-12-15 | Smithkline Beecham Biolog | Multivalente impfstoffzusammensetzung |
| WO2002080964A1 (en) * | 2001-04-06 | 2002-10-17 | Institut Pasteur | Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of vibrio cholerae 0139 bound to tetanus toxoid |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| CN1401328A (zh) * | 2002-10-18 | 2003-03-12 | 北京绿竹生物技术有限责任公司 | 流行性脑脊髓膜炎多糖－蛋白结合疫苗 |
| CN102319427A (zh) * | 2003-01-30 | 2012-01-18 | 诺华疫苗和诊断有限公司 | 抗多种脑膜炎球菌血清组的可注射性疫苗 |
-
2005
- 2005-06-27 GB GBGB0513069.5A patent/GB0513069D0/en not_active Ceased
-
2006
- 2006-06-23 CN CN2006800311786A patent/CN101247827B/zh active Active
- 2006-06-23 CN CN2006800233344A patent/CN101208103B/zh active Active
- 2006-06-23 ES ES06754611.9T patent/ES2367918T5/es active Active
- 2006-06-23 CN CN2006800230577A patent/CN101208101B/zh active Active
- 2006-06-23 CN CN200680023149.5A patent/CN101222935B/zh active Active
- 2006-06-23 UA UAA200714085A patent/UA97233C2/uk unknown
-
2007
- 2007-12-13 ZA ZA200710853A patent/ZA200710853B/xx unknown
- 2007-12-14 ZA ZA200710909A patent/ZA200710909B/xx unknown
- 2007-12-18 ZA ZA200711074A patent/ZA200711074B/xx unknown
-
2012
- 2012-10-18 FR FR12C0060C patent/FR12C0060I2/fr active Active
-
2021
- 2021-05-25 NO NO2021022C patent/NO2021022I1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO2021022I1 (no) | 2021-05-25 |
| ZA200710853B (en) | 2009-04-29 |
| ES2367918T3 (es) | 2011-11-10 |
| CN101208103B (zh) | 2013-04-24 |
| CN101222935B (zh) | 2015-07-29 |
| FR12C0060I1 (zh) | 2012-12-14 |
| CN101208101B (zh) | 2013-01-02 |
| CN101208103A (zh) | 2008-06-25 |
| CN101247827B (zh) | 2013-07-17 |
| ES2367918T5 (es) | 2014-11-21 |
| FR12C0060I2 (fr) | 2017-01-06 |
| CN101222935A (zh) | 2008-07-16 |
| ZA200710909B (en) | 2009-04-29 |
| CN101208101A (zh) | 2008-06-25 |
| CN101247827A (zh) | 2008-08-20 |
| GB0513069D0 (en) | 2005-08-03 |
| ZA200711074B (en) | 2009-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7268125B2 (ja) | コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用 | |
| CA2611964C (en) | Process for manufacturing vaccines | |
| CN106102770B (zh) | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 | |
| RU2762723C2 (ru) | Иммуногенные композиции для применения в пневмококковых вакцинах | |
| US20150079125A1 (en) | Vaccine | |
| JP2022512345A (ja) | 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用 | |
| UA97233C2 (uk) | Процес виробництва вакцин | |
| JP2022075575A (ja) | 肺炎球菌ワクチンにおける使用のための免疫原性組成物 | |
| ZA200107637B (en) | Vaccine. | |
| CN110652585A (zh) | 多糖-蛋白缀合物免疫制剂及其制备与应用 | |
| US20150079129A1 (en) | Vaccine | |
| MXPA01009455A (en) | Vaccine |